Confronto
Amycretin vs. Dulaglutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
nessun dato
923950-08-7
Peso molecolare
nessun dato
59670 g/mol
Emivita
nessun dato
110 h
Sequenza
nessun dato
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcMeccanismo d'azione
Amycretin
Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
5
di cui sull'uomo
1
5
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Amycretin and Dulaglutide?
- Amycretin is classified as "Metabolico", while Dulaglutide is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Amycretin or Dulaglutide?
- The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for Dulaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Amycretin and Dulaglutide in Germany and the United States?
- Germania: Amycretin — Non approvato, Dulaglutide — Su prescrizione. Stati Uniti: Amycretin — Non approvato, Dulaglutide — Su prescrizione. These are factual summaries with source and review date on the individual pages.